David Ricks, Eli Lilly CEO (Paulo Nunes dos Santos/Bloomberg via Getty Images)
October 10, 2024 03:31 PM EDT
Startups
Deals

Eli Lil­ly inks an­oth­er obe­si­ty pact, dou­bling down on small Swiss part­ner

Kyle LaHucik

Senior Reporter

Eli Lil­ly is re­turn­ing to Key­Bio­science, a nim­ble Swiss biotech, sev­en years af­ter orig­i­nal­ly link­ing arms with the start­up to work on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Ex­clu­sive: How an ac­ci­den­tal email tipped Pfiz­er off to an ac­tivist in­vestor’s plan

FDA ap­proves Roche's new treat­ment for sub­set of breast can­cer pa­tients

Star­board launch­es first sal­vo in Pfiz­er fight, al­leg­ing ex-CEO, CFO were pres­sured to flip

Sev­en pa­tients di­ag­nosed with blood can­cer af­ter Skysona treat­ment, new da­ta show

Sen. War­ren urges FTC to ‘care­ful­ly scru­ti­nize’ No­vo-Catal­ent deal over com­pe­ti­tion con­cerns

Grit­stone files for bank­rupt­cy, says it could forge a trans­ac­tion as ear­ly as this month to keep R&D go­ing

A service from the Financial Times